Publication | Closed Access

Alectinib for Patients with ALK Rearrangement–Positive Non–Small Cell Lung Cancer and a Poor Performance Status (Lung Oncology Group in Kyushu 1401)

OncologyCancer ManagementPathologyPoor Performance StatusCancer TreatmentMedicineRadiation OncologyKyushu 1401Lung CancerMolecular OncologyLung Oncology Group